Get the Stockscreener App
1.28
5.79%
0.07
Pyxis Oncology Inc stock is traded at $1.28, with a volume of 384.16K.
It is up +5.79% in the last 24 hours and up +4.07% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.21
Open:
$1.22
24h Volume:
384.16K
Relative Volume:
0.83
Market Cap:
$83.01M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.6957
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
+7.56%
1M Performance:
+4.07%
6M Performance:
-20.00%
1Y Performance:
-59.87%
1-Day Range:
$1.21
$1.29
1-Week Range:
$1.135
$1.29
52-Week Range:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.28 | 83.01M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology shareholders elect three directors at annual meeting - Investing.com
Pyxis Oncology Elects New Directors at Annual Meeting - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ameriprise Financial Inc. Takes $35,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Jane Street Group LLC Grows Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Nuveen Asset Management LLC Cuts Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Deutsche Bank AG - Defense World
ProShare Advisors LLC Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Northern Trust Corp Sells 15,449 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments - TipRanks
Millennium Management LLC Has $4.65 Million Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Consensus PT from Analysts - Defense World
HC Wainwright Weighs in on Pyxis Oncology Q1 Earnings - Defense World
Q2 EPS Estimates for Pyxis Oncology Cut by HC Wainwright - Defense World
Leerink Partnrs Comments on Pyxis Oncology FY2029 Earnings - Defense World
Pyxis Oncology’s (PYXS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Pyxis Oncology (PYXS) Receives Reiterated Buy Rating from Analys - GuruFocus
Dimensional Fund Advisors LP Raises Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology : May 2025 Corporate Deck (9474da) - marketscreener.com
Pyxis Oncology Reports Q1 Loss and Business Update - TipRanks
Pyxis Oncology (PYXS) Advances Cancer Treatment Research | PYXS Stock News - GuruFocus
Pyxis Oncology, Inc. SEC 10-Q Report - TradingView
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology : May 2025 Corporate Deck (c8a9bd) - marketscreener.com
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 12,924 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology to Participate in Two Upcoming Investor Conferences - The Manila Times
Pyxis Oncology, Inc. CEO Lara S. Sullivan to Participate in Upcoming Investor Conferences - Nasdaq
Next-Gen Cancer Drug Developer Pyxis Oncology Sets Major Investor Conference Schedule for May-June - Stock Titan
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - Defense World
New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs - Baystreet.ca
Renaissance Technologies LLC Acquires 133,018 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology Inc (PYXS) is a good investment, but the stock may be overvalued - uspostnews.com
Taking a look at what insiders are doing to gauge the Pyxis Oncology Inc (PYXS)’s direction - knoxdaily.com
Pyxis Oncology reveals promising preclinical data for cancer drug - Investing.com
Pyxis Oncology reveals promising preclinical data for cancer drug By Investing.com - Investing.com UK
Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025 - Nasdaq
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - TradingView
Novel Cancer Drug Shows 91% Tumor Inhibition in Breakthrough Study | PYXS Stock News - Stock Titan
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Pyxis Oncology Inc (PYXS) requires closer examination - uspostnews.com
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance
Pyxis Oncology Inc (PYXS) receives a Mkt perform rating from William Blair - knoxdaily.com
Pyxis Oncology Inc (PYXS) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Sei Investments Co. Acquires New Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
American Century Companies Inc. Has $468,000 Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - marketscreener.com
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):